DAM Capital Advisors Sticks to Its Buy Rating for Samvardhana Motherson International Limited (MOTHERSON)

In a report released yesterday, from DAM Capital Advisors maintained a Buy rating on Samvardhana Motherson International Limited (MOTHERSON – Research Report), with a price target of INR195.00. The company's shares closed last Friday at INR153.12.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Samvardhana Motherson International Limited with a INR154.67 average price target, which is a 1.01% upside from current levels. In a report released on May 30, CLSA also maintained a Buy rating on the stock with a INR182.00 price target.
The company has a one-year high of INR217.00 and a one-year low of INR107.30. Currently, Samvardhana Motherson International Limited has an average volume of 1.09M.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

17 hours ago

• Business Insider

Dassault Systemes price target lowered to EUR 27 from EUR 28 at Jefferies

Jefferies lowered the firm's price target on Dassault Systemes (DASTY) to EUR 27 from EUR 28 and keeps an Underperform rating on the shares. The firm says ongoing macro uncertainty means positive surprises are unlikely in the company's Q2. It believes questions over whether Dassault will meet guidance are persist until year-end. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Business Insider

18 hours ago

• Business Insider

Sarepta price target lowered to $30 from $84 at JPMorgan

JPMorgan lowered the firm's price target on Sarepta (SRPT) to $30 from $84 and keeps an Overweight rating on the shares. The firm made changes to its revenue assumptions for key Elevidys post the disclosure of second non-ambulatory patient death. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Business Insider

18 hours ago

• Business Insider

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

JPMorgan analyst Anupam Rama lowered the firm's price target on Sage Therapeutics (SAGE) to $8.50 from $11 and keeps a Neutral rating on the shares. The firm cites the acquisition deal price by Supernus Pharmaceuticals for the target cut. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>